Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Tissue plasminogen activator Stories

2014-03-04 08:32:11

REHOVOT, Israel, March 4, 2014 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, March 4th, 2014, the successful interim analysis of the first group of stroke patients that completed follow-up in the Phase 2 clinical study of THR-18. The interim report confirms the safety and tolerability of THR-18 at a dose of 0.18mg/kg, administered together with tissue plasminogen activator (tPA) in acute ischemic stroke patients. The interim report gives a green light to proceed to...

2013-11-21 12:27:31

Presented at the 40th Annual VEITHsymposium in New York City NEW YORK, Nov. 21, 2013 /PRNewswire-iReach/ -- Acute pulmonary embolism (PE) is a potentially life-threatening condition, reporting an overall mortality rate of 15% in the first three months after diagnosis. The literature describes a three-tier risk stratification scale (massive, submassive and minor) based on the hemodynamic status and presence of signs/symptoms. Tod C. Engelhardt, MD, Louisiana Heart, Lung and Vascular...

2013-10-30 08:32:39

REHOVOT, Israel, October 30, 2013 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, October 30 2013, that a new patent has been granted in the US and China related to composition and use of THR-18 in thromboembolic diseases and pathological conditions associated with neurological damage. THR-18, a synthetic therapeutic peptide derived from plasminogen activator inhibitor-1 (PAI-1) is currently being studied in a Phase II clinical trial in stroke patients treated with...

2013-10-25 10:22:49

American Heart Association Rapid Access Journal Report A hands-free ultrasound device combined with a clot-busting drug was safe for ischemic stroke patients in a phase II pilot study, reported in the American Heart Association journal Stroke. The device is placed on the stroke patient's head and delivers ultrasound to enhance the effectiveness of the clot-busting drug tissue plasminogen activator (tPA). Unlike the traditional hand-held ultrasound probe that's aimed at a blood clot,...

2013-10-16 08:27:57

REHOVOT, Israel, October 16, 2013 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, October 16th 2013, receipt of approval from the regulatory authorities in the Ukraine to commence a Phase IIa clinical study of THR-18, to be given with the clot buster drug tissue plasminogen activator (tPA), in patients with acute ischemic stroke. THR-18 is a synthetic therapeutic peptide derived from plasminogen activator inhibitor-1 (PAI-1). This is a double-blind,...

2013-10-14 08:25:41

REHOVOT, Israel, October 14, 2013 /PRNewswire/ -- D-Pharm [http://www.dpharm.com ] Ltd (TASE: DPRM) announced today October 14th 2013, that an Investigators Meeting has been scheduled later this month, in Prague, to discuss the clinical protocol for a first feasibility study to test DP-b99 in patients with acute high-risk inflammation of the pancreas (pancreatitis). DP-b99 modulates the activity of a range of metal dependent enzymes involved in the cell death cascade...

2013-08-01 12:28:40

Clinical Trial to Evaluate Novel Ultrasound Treatment at Over 60 Leading Stroke Centers Worldwide REDMOND, Wash., Aug. 1, 2013 /PRNewswire/ -- Cerevast Therapeutics, Inc., a privately-held medical technology company, announced today that it has initiated patient enrollment in its Phase 3 clinical trial evaluating the use of the Company's proprietary Clotbust ER(TM) ultrasonic headframe for the treatment of acute ischemic stroke. This worldwide study intends to enroll up to 800...

2013-07-29 08:26:51

BOSTON and TEL AVIV, Israel, July 29, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("Inspire" or the "Company"), a leader in embolic protection stents, said the first patient has been enrolled in the Master II IDE clinical trial to evaluate the safety and effectiveness of the MGuard(TM) Prime Embolic Protection Stent (EPS) in patients suffering from ST Elevation Myocardial Infarction (STEMI). The multi-center, randomized trial is expected to include up to 70 sites in the...

2013-07-26 13:31:18

American Heart Association Rapid Access Journal Report Women with clot-caused strokes are less likely than men to arrive at the hospital in time to receive the best treatment, according to a European study reported in the American Heart Association journal Stroke. In the study, 11 percent of women with acute ischemic strokes were treated with the clot-dissolving medication alteplase, compared with 14 percent of men. Study participants included 5,515 patients at 12 hospitals in the...

2013-05-16 14:58:11

A new study from the University of Cincinnati (UC) College of Medicine has found that, when delivered via ultrasound, the natural enzyme plasmin is more effective at dissolving stroke-causing clots than the standard of care, recombinant tissue plasminogen activator (rt-PA). The novel delivery method involved trapping plasmin into bubble-like liposomes, delivering them to the clot intravenously and bursting it via ultrasound. That method is necessary, says UC associate professor of...